Literature DB >> 23001868

Serum protein N-glycan alterations of diethylnitrosamine-induced hepatocellular carcinoma mice and their evolution after inhibition of the placental growth factor.

Bram Blomme1, Femke Heindryckx, Jean Marie Stassen, Anja Geerts, Isabelle Colle, Hans Van Vlierberghe.   

Abstract

Placental growth factor (PlGF) inhibition produced promising results in reducing tumor burden in a diethylnitrosamine (DEN)-induced mouse model for hepatocellular carcinoma (HCC). The aim of this study was to non-invasively assess the improved histology by performing a serum glycomic analysis. To elucidate the molecular mechanism underlying the observed glycomic effects, we investigated the transcription and expression of E26 transformation-specific sequence 1 (Ets-1), a transcription factor essential for the glycomic and angiogenic changes in malignant transformation, including its different phosphorylated forms that result from activation of the MAP kinase and a Ca(2+)-dependent pathway. In addition, three Ets-1-dependent glycosyltransferase genes, Mgat4a, Mgat4b, and Mgat5, were also evaluated. HCC was induced in mice by weekly injections with DEN for 16, 20, 25, and 30 w. In the treatment study, mice were injected with DEN for 25 w and subsequently treated with PlGF antibodies (5D11D4) for 5 w. Finally, PlGF-/- mice were injected with DEN for 20, 25, and 30 w. Serum N-glycans were analyzed with DNA sequencer-assisted fluorophore-assisted capillary electrophoresis and compared with histology. Maximum altered N-glycan phenotype was reached after 20 w of DEN-injections, i.e., when the first neoplastic lesions started to appear. 5D11D4-treatment improved the glycomic phenotype in that 7 of the 11 altered glycans tended to normalize. The PlGF-/- mice also showed a normalization trend, although not to the same extent of the treatment group. Number of Ets1, Mgat4a, Mgat4b, and Mgat5 transcripts increased considerably in DEN-injected mice, however, a non-significant decrease was observed after 5D11D4-treatment. On the protein level, 5D11D4-treatment had a prominent effect on the MAP kinase pathway with a significant p38 activation, yet independent of Ets-1 function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23001868     DOI: 10.1007/s11010-012-1461-1

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  38 in total

1.  Transcriptional regulation of the N-acetylglucosaminyltransferase V gene in human bile duct carcinoma cells (HuCC-T1) is mediated by Ets-1.

Authors:  R Kang; H Saito; Y Ihara; E Miyoshi; N Koyama; Y Sheng; N Taniguchi
Journal:  J Biol Chem       Date:  1996-10-25       Impact factor: 5.157

2.  Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage.

Authors:  Jiejie Xu; Xiaojing Yun; Jianhai Jiang; Yuanyan Wei; Yihong Wu; Wei Zhang; Yeheng Liu; Wenzhong Wang; Yumei Wen; Jianxin Gu
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

3.  Regulation of the GnT-V promoter by transcription factor Ets-1 in various cancer cell lines.

Authors:  J H Ko; E Miyoshi; K Noda; A Ekuni; R Kang; Y Ikeda; N Taniguchi
Journal:  J Biol Chem       Date:  1999-08-13       Impact factor: 5.157

4.  Ets1 is an effector of protein kinase Calpha in cancer cells.

Authors:  Martina Vetter; Sibylle G Blumenthal; Ralph K Lindemann; Joachim Manns; Sebastian Wesselborg; Christoph Thomssen; Jürgen Dittmer
Journal:  Oncogene       Date:  2005-01-20       Impact factor: 9.867

Review 5.  Hepatocellular carcinoma: epidemiology, risk factors, and screening.

Authors:  Morris Sherman
Journal:  Semin Liver Dis       Date:  2005       Impact factor: 6.115

6.  Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.

Authors:  Christian Fischer; Bart Jonckx; Massimiliano Mazzone; Serena Zacchigna; Sonja Loges; Lucia Pattarini; Emmanuel Chorianopoulos; Laurens Liesenborghs; Marta Koch; Maria De Mol; Monica Autiero; Sabine Wyns; Stephane Plaisance; Lieve Moons; Nico van Rooijen; Mauro Giacca; Jean-Marie Stassen; Mieke Dewerchin; Desire Collen; Peter Carmeliet
Journal:  Cell       Date:  2007-11-02       Impact factor: 41.582

7.  Physiological and glycomic characterization of N-acetylglucosaminyltransferase-IVa and -IVb double deficient mice.

Authors:  Shinji Takamatsu; Aristotelis Antonopoulos; Kazuaki Ohtsubo; David Ditto; Yasunori Chiba; Dzung T Le; Howard R Morris; Stuart M Haslam; Anne Dell; Jamey D Marth; Naoyuki Taniguchi
Journal:  Glycobiology       Date:  2009-12-16       Impact factor: 4.313

Review 8.  p38alpha: a suppressor of cell proliferation and tumorigenesis.

Authors:  Lijian Hui; Latifa Bakiri; Ewa Stepniak; Erwin F Wagner
Journal:  Cell Cycle       Date:  2007-10-21       Impact factor: 4.534

9.  Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma.

Authors:  Femke Heindryckx; Koen Mertens; Nicolas Charette; Bert Vandeghinste; Christophe Casteleyn; Christophe Van Steenkiste; Dominique Slaets; Louis Libbrecht; Steven Staelens; Peter Starkel; Anja Geerts; Isabelle Colle; Hans Van Vlierberghe
Journal:  Mol Cancer       Date:  2010-08-20       Impact factor: 27.401

10.  Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor.

Authors:  D Maglione; V Guerriero; G Viglietto; P Delli-Bovi; M G Persico
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

View more
  6 in total

1.  Insights into glycan biosynthesis in chemically-induced hepatocellular carcinoma in rats: A glycomic analysis.

Authors:  Amr Amin; Asma Bashir; Nazar Zaki; Diane McCarthy; Sanjida Ahmed; Mohamed Lotfy
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

2.  The transcriptional profiling of glycogenes associated with hepatocellular carcinoma metastasis.

Authors:  Tianhua Liu; Shu Zhang; Jie Chen; Kai Jiang; Qinle Zhang; Kun Guo; Yinkun Liu
Journal:  PLoS One       Date:  2014-09-18       Impact factor: 3.240

3.  Construction of a set of novel and robust gene expression signatures predicting prostate cancer recurrence.

Authors:  Yanzhi Jiang; Wenjuan Mei; Yan Gu; Xiaozeng Lin; Lizhi He; Hui Zeng; Fengxiang Wei; Xinhong Wan; Huixiang Yang; Pierre Major; Damu Tang
Journal:  Mol Oncol       Date:  2018-08-11       Impact factor: 6.603

4.  MicroRNA-4491 enhances cell proliferation and inhibits cell apoptosis in non-small cell lung cancer via targeting TRIM7.

Authors:  Fei Han; Gang Chen; Yi Guo; Bo Li; Yanlong Sun; Xiangqian Qi; Hanji Tian; Xinfei Zhao; Hongguang Zhang
Journal:  Oncol Lett       Date:  2021-06-07       Impact factor: 2.967

5.  Generalized portrait of cancer metabolic pathways inferred from a list of genes overexpressed in cancer.

Authors:  Eugenia Poliakov; David Managadze; Igor B Rogozin
Journal:  Genet Res Int       Date:  2014-08-27

6.  Specific N-glycans of Hepatocellular Carcinoma Cell Surface and the Abnormal Increase of Core-α-1, 6-fucosylated Triantennary Glycan via N-acetylglucosaminyltransferases-IVa Regulation.

Authors:  Huan Nie; Xia Liu; Yubao Zhang; Tingting Li; Chao Zhan; Wenjuan Huo; Anshun He; Yuanfei Yao; Yu Jin; Youpeng Qu; Xue-Long Sun; Yu Li
Journal:  Sci Rep       Date:  2015-11-05       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.